Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Neurology

• Publication date

  2004-09-14

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/01.WNL.0000137040.64252.EDPMID 15365131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endogenous estradiol and risk of dementia in women and men: The Rotterdam Study

  2003cited by this paper
• Onset of dementia is associated with age at menopause in women with Down's syndrome

  2003cited by this paper
• Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

  2003cited by this paper
• Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

  2003cited by this paper
• Hormone therapy and the brain: déjà vu all over again?

  2003cited by this paper
• Serum creatinine levels correlate with plasma amyloid β protein

  2002cited by this paper
• Serum Creatinine Levels Correlate With Plasma Amyloid &bgr; Protein

  2002cited by this paper
• The Effects of Estrogen Replacement Therapy on Neuropsychological Functioning in Postmenopausal Women With and Without Dementia: A Critical and Theoretical Review

  2002cited by this paper
• Modulation of Aβ peptides by estrogen in mouse models

  2002cited by this paper
• Ovariectomy of young mutant amyloid precursor protein transgenic mice leads to increased mortality

  2002cited by this paper
• Cholesterol in Alzheimer's Disease and Tauopathy

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease

  2001cited by this paper
• Mild cognitive impairment represents early-stage Alzheimer disease.

  2001cited by this paper
• Current concepts in mild cognitive impairment.

  2001cited by this paper
• Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

  2001cited by this paper
• Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

  2001cited by this paper
• Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease

  2000cited by this paper
• Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

  2000cited by this paper
• Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma.

  2000cited by this paper
• Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease

  1999cited by this paper
• Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease.

  1999cited by this paper
• Formal education as an effect modifier of the relationship between Mini-Mental State Examination score and IADLs disability in the older population

  1997cited by this paper
• Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

  1996cited by this paper
• Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.

  1996cited by this paper
• Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

  1996cited by this paper
• Amyloid β protein in plasma from patients with sporadic Alzheimer's disease

  1996cited by this paper
• Apolipoprotein E genotyping in Alzheimer's disease.

  1996cited by this paper
• Apolipoprotein E genotyping in Alzheimer's disease.

  1996cited by this paper
• Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

  1996cited by this paper
• Estrogen deficiency and risk of Alzheimer's disease in women.

  1994cited by this paper
• Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein.

  1994cited by this paper
• Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide

  1993cited by this paper
• Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

  1990cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Development and validation of a geriatric depression screening scale: a preliminary report.

  1982cited by this paper
• CME Practice parameter:

  year unknowncited by this paper

• Probable chronic pain, brain structure, and Alzheimer's plasma biomarkers in older men.

  2024cites this paper
• Prominent Perspective on Existing Biological Hallmarks of Alzheimer's Disease.

  2024cites this paper
• Elevated C-Reactive Protein in Older Men With Chronic Pain: Association With Plasma Amyloid Levels and Hippocampal Volume

  2024cites this paper
• Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis

  2022cites this paper
• Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects

  2022cites this paper
• CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice

  2021cites this paper
• The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression

  2021cites this paper
• Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease

  2020cites this paper
• Increased Contact System Activation in Mild Cognitive Impairment Patients with Impaired Short-Term Memory

  2020cites this paper
• Amyloid‐beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome

  2020cites this paper
• Plasma Amyloid Concentration in Alzheimer’s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer’s Disease Cases from Controls

  2020cites this paper
• Long‐term and in vivo assessment of Aβ protein‐induced brain atrophy in a zebrafish model by optical coherence tomography

  2020cites this paper
• Current and Developing Methods for Diagnosing Alzheimer's Disease

  2019cites this paper
• Amyloid-β as a Blood Biomarker for Alzheimer’s Disease: A Review of Recent Literature

  2019cites this paper
• Quantitative metabolic biomarker analysis of mild cognitive impairment in eastern U.P. and Bihar population.

  2019cites this paper
• Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer’s Disease

  2019cites this paper
• Exploring Relationships Among Peripheral Amyloid Beta, Tau, Cytokines, Cognitive Function, and Psychosomatic Symptoms in Breast Cancer Survivors

  2019cites this paper
• Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment

  2019cites this paper
• Progress and Challenges in the Diagnosis of Dementia: A Critical Review.

  2018cites this paper
• Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers

  2018cites this paper
• Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition

  2017cites this paper
• Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer’s disease

  2017cites this paper
• Abnormal amyloid β42 expression and increased oxidative stress in plasma of CKD patients with cognitive dysfunction: A small scale case control study comparison with Alzheimer's disease

  2017cites this paper
• The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration

  2017cites this paper
• Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics.

  2017cites this paper
• The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study.

  2016cites this paper
• Plasma Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men

  2016cites this paper
• Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimer's disease patients: search for a potential biomarker

  2016cites this paper
• Origin(s) of Intraneuronal Amyloid

  2016cites this paper
• Increased levels of plasma amyloid-beta are related to cortical thinning and cognitive decline in cognitively normal elderly subjects.

  2015influential citation
• Amnestic Mild Cognitive Impairment and Conversion to Alzheimer's Disease: Insulin Resistance and Glycoxidation as Early Biomarker Clusters

  2015cites this paper
• Biomarkers in Sporadic and Familial Alzheimer’s Disease

  2015cites this paper
• Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.

  2015cites this paper
• Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.

  2015cites this paper
• Protein-Based Biomarkers in Cerebrospinal Fluid and Blood for Alzheimer’s Disease

  2014cites this paper
• Clusterin as a blood biomarker for diagnosis of mild cognitive impairment and Alzheimer's disease

  2014cites this paper
• Detection of novel serological biomarkers in two neurodegenerative disorders

  2014cites this paper
• Amyloid-β Induces Hepatic Insulin Resistance In Vivo via JAK2

  2013cites this paper
• What’s hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders

  2013cites this paper
• Metabolic Syndrome as a Risk Factor for Alzheimer Disease

  2013cites this paper
• Multiplex biomarkers in blood

  2013cites this paper
• Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

  2013influential citation
• Association between the characteristics of metabolic syndrome and Alzheimer’s disease

  2013cites this paper
• Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.

  2013cites this paper
• Metabolic Syndrome

  2013cites this paper
• Amyloid-β Induces Hepatic Insulin Resistance by Activating JAK2/STAT3/SOCS-1 Signaling Pathway

  2012cites this paper
• Synaptotoxic Amyloid-β Oligomers: A Molecular Basis for the Cause, Diagnosis, and Treatment of Alzheimer's Disease?

  2012cites this paper
• Variability in Blood-Based Amyloid-β Assays: The Need for Consensus on Pre-Analytical Processing

  2012cites this paper
• Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD

  2012cites this paper
• Plasma biomarkers for Alzheimer's disease: much needed but tough to find.

  2012cites this paper
• Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment

  2012cites this paper
• The Current Status of Alzheimer's Disease Treatment

  2012cites this paper
• Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer's Disease

  2012cites this paper
• Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer's disease?

  2011cites this paper
• Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease.

  2011cites this paper
• Effect of Anticoagulants on Amyloid β-Protein Precursor and Amyloid Beta Levels in Plasma.

  2011cites this paper
• Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

  2011cites this paper
• Identifying and validating biomarkers for Alzheimer's disease

  2011cites this paper
• Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice

  2011cites this paper
• Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.

  2011cites this paper
• Plasma (cid:2) -Amyloid and Cognitive Decline

  2010cites this paper
• The H1 Haplotype of the Tau Gene (MAPT) is Associated with Mild Cognitive Impairment

  2010cites this paper
• Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging

  2010cites this paper
• Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

  2010cites this paper
• Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study

  2010cites this paper
• Anti-inflammatory therapy and cerebrospinal fluid diagnosis in Alzheimer's disease.

  2010cites this paper
• Plasma ß-amyloid and cognitive decline.

  2010cites this paper
• Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects.

  2010cites this paper
• Amyloid-β42 Plasma Levels are Elevated in Amnestic Mild Cognitive Impairment

  2009influential citation
• Serum β-Amyloid Correlates with Neuropsychological Impairment

  2009cites this paper
• Peripheral Biomarkers in Dementia and Alzheimer's Disease

  2009cites this paper
• Blood protein signature for the early diagnosis of Alzheimer disease.

  2009cites this paper
• Depression and Plasma Amyloid β Peptides in the Elderly With and Without the Apolipoprotein E4 Allele

  2009cites this paper
• Troponin and S100β are associated with depression in healthy older adults

  2009cites this paper
• Balance Features in Alzheimer's Disease and Amnestic Mild Cognitive Impairment

  2009cites this paper
• A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.

  2009cites this paper
• The handbook of neuropsychiatric biomarkers, endophenotypes and genes

  2009cites this paper
• Prevalence of four subtypes of mild cognitive impairment and APOE in a Japanese community

  2009cites this paper
• Strategies for Alzheimer's Disease Diagnosis

  2009cites this paper
• The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down Syndrome

  2009cites this paper
• Amyloid beta oligomers induce impairment of neuronal insulin receptors

  2008cites this paper
• Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.

  2008cites this paper
• A 74-year-old man with memory loss and neuropathy who enjoys alcoholic beverages.

  2008cites this paper
• CSF biomarkers in dementia: longitudinal aspects and combination with MRI

  2008cites this paper
• Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker?

  2008cites this paper
• Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease

  2008cites this paper
• Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

  2008cites this paper
• Luteinizing Hormone Levels Are Positively Correlated with Plasma Amyloid-β Protein Levels in Elderly Men

  2008cites this paper
• Amyloid-associated depression: a prodromal depression of Alzheimer disease?

  2008cites this paper
• Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.

  2008cites this paper
• Maximizing the Potential of Plasma Amyloid-Beta as a Diagnostic Biomarker for Alzheimer’s Disease

  2008cites this paper
• Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.

  2008cites this paper
• Elevated plasma amyloid β-peptide Aβ42, incident dementia and mortality in Down syndrome

  2007cites this paper
• Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

  2007cites this paper
• Relation of Plasma Homocysteine to Plasma Amyloid Beta Levels

  2007cites this paper
• Alzheimer's disease in Down syndrome: neurobiology and risk.

  2007cites this paper
• Plasma Abeta levels do not reflect brain Abeta levels.

  2007cites this paper
• Current state and future directions of neurochemical biomarkers for Alzheimer's disease.

  2007cites this paper
• New Possibilites for Early Diagnosis of Alzheimer Disease: "Alzheimer Associated Gene" and Blood Biomarkers Nowe możliwości sprzyjające wczesnemu rozpoznawaniu choroby Alzheimera: "Alzheimer Associated Gene" i biomarkery krwi

  2007cites this paper
• Plasma A b peptides and apolipoprotein E in sporadic Alzheimer ’ s disease and mild cognitive impairment

  2007cites this paper